Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 405629, 9 pages
http://dx.doi.org/10.1155/2015/405629
Research Article

ISU201 Enhances the Resolution of Airway Inflammation in a Mouse Model of an Acute Exacerbation of Asthma

1Inflammation and Infection Research, School of Medical Sciences, UNSW Australia, Sydney, NSW 2052, Australia
2Isu Abxis Co., Ltd., 696-1 Sampyeong-dong, Bundang-ku, Seongnam 463-400, Republic of Korea

Received 4 December 2014; Revised 7 January 2015; Accepted 12 January 2015

Academic Editor: Sandra Helena Penha Oliveira

Copyright © 2015 Yuka Hiroshima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. K. Kumar and P. K. Jeffery, “Pathology of asthma,” in Middleton's Allergy, N. F. Adkinson, B. S. Bochner, W. Burks et al., Eds., pp. 986–999, Elsevier, Cambridge, UK, 8th edition, 2013. View at Google Scholar
  2. H. K. Reddel, D. R. Taylor, E. D. Bateman et al., “An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 1, pp. 59–99, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Bahadori, M. M. Doyle-Waters, C. Marra et al., “Economic burden of asthma: a systematic review,” BMC Pulmonary Medicine, vol. 9, article 24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. de Magalhães Simões, M. A. dos Santos, M. da Silva Oliveira et al., “Inflammatory cell mapping of the respiratory tract in fatal asthma,” Clinical and Experimental Allergy, vol. 35, no. 5, pp. 602–611, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. P. J. Barnes, “New therapies for asthma: is there any progress?” Trends in Pharmacological Sciences, vol. 31, no. 7, pp. 335–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Beasley, M. Weatherall, P. Shirtcliffe, R. Hancox, and H. K. Reddel, “Combination corticosteroid/β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma?” Journal of Allergy and Clinical Immunology, vol. 133, no. 1, pp. 39–41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. B. J. Lipworth, “Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis,” Archives of Internal Medicine, vol. 159, no. 9, pp. 941–955, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. B. J. Lipworth and C. M. Jackson, “Safety of inhaled and intranasal corticosteroids. Lessons for the new millennium,” Drug Safety, vol. 23, no. 1, pp. 11–33, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Durham, I. M. Adcock, and O. Tliba, “Steroid resistance in severe asthma: current mechanisms and future treatment,” Current Pharmaceutical Design, vol. 17, no. 7, pp. 674–684, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Wang, J. J. Li, P. S. Foster, P. M. Hansbro, and M. Yang, “Potential therapeutic targets for steroid-resistant asthma,” Current Drug Targets, vol. 11, no. 8, pp. 957–970, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. I. J. M. Doull, F. C. Lampe, S. Smith, J. Schreiber, N. J. Freezer, and S. T. Holgate, “Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial,” British Medical Journal, vol. 315, no. 7112, pp. 858–862, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. L. A. J. O'Neill, “Targeting signal transduction as a strategy to treat inflammatory diseases,” Nature Reviews Drug Discovery, vol. 5, no. 7, pp. 549–563, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Yoo, S.-H. Park, S.-K. Ye, and M. Kim, “IFN-γ-induced BST2 mediates monocyte adhesion to human endothelial cells,” Cellular Immunology, vol. 267, no. 1, pp. 23–29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Temelkovski, S. P. Hogan, D. P. Shepherd, P. S. Foster, and R. K. Kumar, “An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen,” Thorax, vol. 53, no. 10, pp. 849–856, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. S. Siegle, N. Hansbro, C. Herbert, M. Yang, P. S. Foster, and R. K. Kumar, “Airway hyperreactivity in exacerbation of chronic asthma is independent of eosinophilic inflammation,” The American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 5, pp. 565–570, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. T. Nials and S. Uddin, “Mouse models of allergic asthma: acute and chronic allergen challenge,” Disease Models and Mechanisms, vol. 1, no. 4-5, pp. 213–220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Herbert, A. M. Shadie, M. M. Bunting et al., “Anti-inflammatory and anti-remodelling effects of ISU201, a modified form of the extracellular domain of human BST2, in experimental models of asthma: association with inhibition of histone acetylation,” PLoS ONE, vol. 9, no. 3, Article ID e90436, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. C. N. Serhan, S. D. Brain, C. D. Buckley et al., “Resolution of inflammation: state of the art, definitions and terms,” The FASEB Journal, vol. 21, no. 2, pp. 325–332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. R. P. Flesher, C. Herbert, and R. K. Kumar, “Resolvin E1 promotes resolution of inflammation in a mouse model of an acute exacerbation of allergic asthma,” Clinical Science, vol. 126, no. 11, pp. 805–814, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Schneider and A. C. Issekutz, “Quantitation of eosinophil and neutrophil infiltration into rat lung by specific assays for eosinophil peroxidase and myeloperoxidase. Application in a Brown Norway rat model of allergic pulmonary inflammation,” Journal of Immunological Methods, vol. 198, no. 1, pp. 1–14, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. Greenberg, G. Kerby, and G. E. Roosevelt, “A comparison of oral dexamethasone with oral prednisone in pediatric asthma exacerbations treated in the emergency department,” Clinical Pediatrics, vol. 47, no. 8, pp. 817–823, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Castro, S. Mathur, F. Hargreave et al., “Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study,” The American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 10, pp. 1125–1132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Corren, W. Busse, E. O. Meltzer et al., “A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 8, pp. 788–796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. E. Wenzel, P. J. Barnes, E. R. Bleecker et al., “A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma,” The American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 7, pp. 549–558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. G. M. Walsh, “An update on emerging drugs for asthma,” Expert Opinion on Emerging Drugs, vol. 17, no. 1, pp. 37–42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Herbert, A. Hettiaratchi, D. C. Webb, P. S. Thomas, P. S. Foster, and R. K. Kumar, “Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma,” Clinical and Experimental Allergy, vol. 38, no. 5, pp. 847–856, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. G. Royce, Y. R. Miao, M. Lee, C. S. Samuel, G. W. Tregear, and M. L. K. Tang, “Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease,” Endocrinology, vol. 150, no. 6, pp. 2692–2699, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. A. L. Alessandri, L. P. Sousa, C. D. Lucas, A. G. Rossi, V. Pinho, and M. M. Teixeira, “Resolution of inflammation: mechanisms and opportunity for drug development,” Pharmacology and Therapeutics, vol. 139, no. 2, pp. 189–212, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Liu, J. M. Cousin, J. Hughes et al., “Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes,” Journal of Immunology, vol. 162, no. 6, pp. 3639–3646, 1999. View at Google Scholar · View at Scopus
  30. N. Wallen, H. Kita, D. Weiler, and G. J. Gleich, “Glucocorticoids inhibit cytokine-mediated eosinophil survival,” Journal of Immunology, vol. 147, no. 10, pp. 3490–3495, 1991. View at Google Scholar · View at Scopus
  31. X. Zhang, E. Moilanen, and H. Kankaanranta, “Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone,” European Journal of Pharmacology, vol. 406, no. 3, pp. 325–332, 2000. View at Publisher · View at Google Scholar · View at Scopus